Previous 10 | Next 10 |
2023-11-02 16:59:53 ET More on Galapagos Galapagos: Good To Have An Approval, Bad To Have No Major Catalysts Galapagos Q3 2023 Earnings Preview Galapagos concludes strategic evaluation and signs letter of intent to transfer Jyseleca business to Alfasigma Seek...
First nine months 2023 key financials: Group revenues of €448.9 million Jyseleca® net sales of €82.1 million Cash and current financial investments of €3.8 billion at 30 September 2023 Full year 2023 net Jyseleca® sales guidance of ...
Acushnet Holdings Corp. (GOLF) is expected to report $0.54 for Q3 2023 Paramount Global (PARA) is expected to report $0.09 for Q3 2023 Curis Inc. (CRIS) is expected to report $-2.32 for Q3 2023 Quanta Services Inc. (PWR) is expected to report $1.99 for Q3 2023 GRI Bio Inc. (GRI) i...
Galapagos NV (GLPG) is expected to report $-0.74 for Q3 2023
2023-10-30 16:10:56 ET More on Galapagos Galapagos: Good To Have An Approval, Bad To Have No Major Catalysts Galapagos cut to Neutral at Citi on lack of catalysts Seeking Alpha’s Quant Rating on Galapagos Historical earnings data for Galapagos ...
Transaction would enable Galapagos to realize considerable annualized savings and accelerate its pipeline focused on developing transformational medicines Aims to preserve the Jyseleca® (filgotinib) business and a significant number of positions Galapagos plans to streamline ...
Mechelen, Belgium; 1 9 September 2023, 22:01 CET ; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that during its meeting of 19 September 2023 , the Board of Directors appointed Mr. Simon Sturge as N o n- E ...
GLPG3667 is an investigational, novel, oral, reversible, and selective tyrosine kinase 2 (TYK2) inhibitor GLPG3667 is currently in development for the treatment of inflammatory and auto-immune diseases and is in Phase 2 for d ermatomyositis Mechelen, Belgium; 28 ...
2023-08-24 10:55:38 ET More on Galapagos Galapagos NV ( GLPG ) Q2 2023 Earnings Call Transcript Galapagos to transfer drug discovery and research activities in France to NovAliX Galapagos stock dips as Jyseleca fails phase 3 trial as induction therapy in Crohn's ...
2023-08-04 16:30:18 ET Galapagos NV (GLPG) Q2 2023 Results Conference Call August 04, 2023 08:00 AM ET Company Participants Sofie Van Gijsel - Head, IR Paul Stoffels - CEO, Chairman, Interim Head, R&D Thad Huston - CFO and COO Michele Manto - Chief Commer...
News, Short Squeeze, Breakout and More Instantly...
2024-07-11 21:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next-generation MAGE-A4 TCR T-cell therapy) produced on Galapagos' decentralized manufacturing platform in patients with head & neck cancer Uza-cel has shown encouraging resul...